Negative serology of Fasciola hepatica infection in patients with liver cancer in Peru: a preliminary report

Abstract INTRODUCTION: The etiology of several hepatocellular carcinoma (HCC) cases remains largely unknown. Although Fasciola hepatica has been associated with liver fibrosis in Latin America, it has not yet been associated with HCC. This study aimed to determine the existence of specific IgG antibodies against F. hepatica in the serum samples of HCC patients. METHODS In total, 13 serum samples from 13 HCC patients were screened using Fas2-ELISA. RESULTS Fas2-ELISA demonstrated negative results in all HCC patients included in this study. CONCLUSIONS The pre-existence of F. hepatica infection in HCC patients needs to be further investigated in epidemiological and experimental studies.

Cáncer gástrico localizado: resultados quirúrgicos de 801 pacientes tratados con linfadenectomia D2 / Surgical outcome of 801 patients with localized gastric cancer treated with D2 lymphadenectomy

ANTECEDENTES: La gastrectomía D2 es un procedimiento considerado inconveniente por la alta mortalidad y la falta de beneficio en la sobrevida. Sin embargo estudios recientes demuestran que también en occidente la D2 tiene baja mortalidad e impacto en la sobrevida. En el instituto de enfermedades neoplasicas la gastrectomía D2 se realiza desde 1990 después del entrenamiento de algunos de los autores en el NCC de Tokio Japón. El objetivo de este estudio es evaluar la mortalidad peri operatoria y sobrevida en un grupo de pacientes quienes tuvieron una gastrectomía D2 (con preservación de páncreas) de acuerdo a las reglas de la Japanese Research Society for Gastric Cancer.. Los datos fueron recolectados prospectivamente y los pacientes fueron seguidos por un mínimo de 7 años. METODOS: Una serie de 938 pacientes con cáncer gástrico localizado fueron admitidos al INEN entre 1990 y 1999, de estos 801 pacientes tuvieron una reseccion curativa D2. Se analizo la mortalidad post operatoria, tipo de gastrectomía, promedio de ganglios linfáticos resecados, estadios TNM y tiempo de sobrevida. RESULTADOS: Se realizo 511 gastrectomias sub total distal y 290 gastrectomias totales, el promedio de ganglios resecados fue de 46.8 por ciento (54.9 ganglios para total y 41.69 para sub total). La mortalidad hospitalaria fue de 2.9 por ciento. 11 por ciento fueron estadio TNM IA, 9.4 por ciento estadio IB, 24.6 por ciento estadio IIIA, 13.1 por ciento estadio IIIB y 23 por ciento estadio IV.La sobrevida a5 años fue de 47.5 por ciento , la sobrevida a 5 años para los estadios IA, IB, II, IIIA, IIIB y IV fue de 85.8 por ciento , 79.4 por ciento , 60 por ciento , 46.7 por ciento 33 por ciento and 14.3 por ciento respectivamente...

BACKGROUND: D2 gastrectomy has been regarded as an inconvenient procedure with high morbidity and no survival benefit in the West. Recent studies, however, have shown low mortality and a survival benefit of D2 gastrectomy. In the Instituto de Enfermedades Neoplasicas (INEN) of Lima Peru D2 gastrectomy is performed since 1990 after training of some of the authors in the NCC of Tokio Japan. Distal Pancreatectomy was performed only if the pancreas was involved. The aim of this study was to evaluate the peri operative mortality and survival in a group of patients who had a standard D2 lymphadenectomy according to the rules of the Japanese Research Society for Gastric Cancer. Data were collected prospectively, and patients were followed for more than 7 years.METHODS: Between 1990 and 1999, 938 patients with localized gastric cancer were registered at INEN. Of these, 801 patients underwent curative resection with extended lymphadenectomy (D2). Post operative morbidity/mortality, type of gastrectomy, mean of lymph nodes removed, pTNM stages and Survival Time and were analyzed. RESULTS: Sub total distal gastrectomy was performed in 511 patients and total gastrectomy in 290 patients. The mean number of lymph nodes removed was 46.48 per patient (54.91 nodes for total and 41.69 for sub total distal gastrectomy). Hospital mortality was 2.9 percent. 11 percent were Stage (TNM) IA, 9.4 percent stage IB, 19 percent stage II, 24.6 percent stage IIIA, 13.1 percent stage IIIB and 23 percent stage IV. Five-year actuarial survival was 47.5 percent. Five-year survival of patients with TNM stages IA, IB, II, IIIA, IIIB and IV were 85.8 percent, 79.4 percent, 60 percent, 46.7 percent 33 percent and 14.3 percent respectively...